(Date:1/7/2009)...c. (NYSE: WLP ) announced,today that senior mana...J.P.,Morgan Healthcare Conference on Jan. 12, 2009...astern Standard Time). , WellPoint, Inc. is sc...months ended Dec. 31, 2008, on January 28, 2009. W...r to this scheduled earnings release, and therefor...
(Date:1/7/2009)...ises, Inc. (BME), a cutting edge medical device co...mory metal implants, announced today that it has a...f Executive Officer. W. Casey Fox, PhD, P.E., BME...nd continue to focus his efforts on building BME,s...es in nitinol implants that contract and compress ...
(Date:1/7/2009)...the troubles of those born at 39 weeks, , ...ng an elective repeat C-section should wait until ...have the baby, if there are no medical issues with...ing just two weeks earlier doubles the risk that t...ing, infection and low blood sugar, according to t...
(Date:1/7/2009)...known as Emily,s Law, has received Governor Ted St...l in the state of Ohio. Named after Emily Jerry, E...gulations for pharmacy technicians. The law, which... was drafted with assistance of the National Pharm... Emily Jerry died at the age of two as the result ...
Breaking Medicine News(10 mins):Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer 2Health News:Early Elective C-Sections Produce Complications 2Health News:Early Elective C-Sections Produce Complications 3Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 3... aside promises of slimmer portions and healthy me...ze version// of the Big Mac, now to be made 40 per...sized burger, expected to contain at least 690 cal...orld Cup promotion for the summer. Vigorous advert...
...offering "bloodless surgery" to almost 90% of its ...now joins an ever-growing number of hospitals that...ne around the country. This option was once only ...is now provided in certain hospitals to more patie...
...d hence various organizations are putting in their...nizations are working towards the complete eradica...One such step is taken by the Manipur AIDS Control...al organizations (NGOs) who are thriving day and n...
...dical negligence, surgeons have reported the remov...ide the patient's abdomen three years ago//. The f...r old Pakistani patient while she had underwent ap...consisting of three senior surgeons and four param...
Other Medicine News:(Date:1/7/2009).../ -- ImQuest Life Sciences announced today the suc...od and Drug Administration to initiate human clini...bitor IQP-0410. ImQuest anticipates initiating the...QP-0410 is a novel small molecule inhibitor of HIV...ranscriptase inhibitor (NNRTI). The compound posse...
(Date:1/6/2009)...lts from prior U.S., U.K. and China Trials , , ... Inc. (VTI), a development stage company targeting... has begun for a randomized, controlled, multi-cen...tracorporeal Liver Assist Device (ELAD) as a treat...nder three protocols. The study is open for enroll...
(Date:1/6/2009)...-USNewswire/ -- Sequella, Inc., a clinical-stage b...idemic potential, announced today that SQ109, its ...sis (TB), was the first drug approved for evaluati... Dynport Vaccine Company LLC and Quintiles Transna...itute of Allergy and Infectious Diseases (NIAID), ...
(Date:1/5/2009)...Cylene Pharmaceuticals announced today that it has...2 protein kinase inhibitor, CX-4945, in patients w... multiple myeloma. The primary endpoints of the or...ty, tolerance and PK properties of CX-4945 and to ...n addition, multiple mechanism-related pharmacodyn...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Raydiance collaborates with Rutgers MTF to develop innovative tissue processing approaches 1269 1Raydiance collaborates with Rutgers MTF to develop innovative tissue processing approaches 1269 2MU study finds that sitting may increase risk of disease 1265 1MU study finds that sitting may increase risk of disease 1265 2MU study finds that sitting may increase risk of disease 1265 3New HPV vaccine under study 6618 1New HPV vaccine under study 6618 2Stress hormone may hasten the progression of certain blood cancers 6614 1Stress hormone may hasten the progression of certain blood cancers 6614 2Stress hormone may hasten the progression of certain blood cancers 6614 3...Kinetics Profile, LAUSANNE, Switzerland, April 19,...), a global independent biopharmaceutical,developm...ditions,presented additional results of a previou...hibitor Debio 025 in HIV/HCV (hepatitis C,virus) c...e 42nd,Annual Meeting of the European Association ...
...USINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,...aceutical,company, discussed results from two pre-...erapy induced angiogenesis and,rationale for combi...spension (paclitaxel protein-bound particles for i...nhibitor drugs like,bevacizumab (Avastin(R)) at th...
Other Medicine Technology:Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: